How to Read an N-of-1 Trial: A Randomized Experiment in a Single Patient

An N-of-1 trial applies the machinery of a randomized trial to one person, cycling that patient through several pairs of treatment periods in a random, usually blinded order to see which works better for them. It is a genuine experiment, not a case report, and for a chronic stable condition with a fast-acting, reversible treatment it can give an individual a far more reliable answer than trial-and-error. Reading one means checking that the periods were randomized and blinded, that washouts guarded against carryover, and being clear that the result speaks to that one patient rather than to a population.

A trial with one participant

An N-of-1 trial takes the tools of a randomized controlled trial and points them at a single patient. Instead of comparing one group of people against another, it compares one person against themselves across repeated treatment periods. The patient receives one treatment, then another, in paired periods that are cycled several times, with the order within each pair assigned at random and, wherever possible, both patient and clinician blinded to which is which.

This is what separates an N-of-1 trial from ordinary trial-and-error prescribing. Trying a drug and seeing how someone feels is uncontrolled and open to expectation and natural fluctuation. Randomizing and blinding repeated periods, then comparing the outcomes systematically, turns that guesswork into a small but real experiment.

Why repetition and blinding matter

A single on-and-off comparison in one person could be a coincidence: the patient might have improved anyway, or expected to improve. An N-of-1 trial guards against this by repeating the comparison several times. If the same treatment comes out ahead across multiple randomized pairs, that consistency is hard to explain by chance or expectation alone.

Blinding does the rest of the work. When neither the patient nor the person assessing the outcome knows which treatment is active in a given period, the comparison is protected from the placebo response and from wishful interpretation. As in a full crossover trial, a washout between periods keeps the previous treatment from carrying into the next, and the analysis compares the patient's outcomes within each pair rather than lumping the periods together.

When a single-patient trial is the right tool

N-of-1 trials fit the same conditions that suit any crossover design, now applied to one person. The condition should be chronic and stable, so it does not resolve or lurch around on its own during the trial. The treatment should act quickly, so a short period is enough to see its effect, and be reversible, so stopping it returns the patient toward baseline before the next period.

They are especially valuable where population evidence runs out. For a rare disease, an unusual combination of conditions, or a patient on several other therapies who would never fit a conventional trial, an N-of-1 trial offers a way to generate real evidence for that individual. It answers the question the patient actually has, which is not whether a drug helps people in general but whether it helps them.

What the result does and does not mean

The strength of an N-of-1 trial is also its boundary. A well-run one gives a trustworthy answer for the person who took part, and that is exactly what individualized care needs. It does not, on its own, tell you what will happen in the next patient, because it studied a sample of one.

There is a bridge to broader knowledge. When several N-of-1 trials are planned in advance around the same question and their results are pooled, the series can support conclusions about a wider group, a design the reporting guidance explicitly distinguishes from a single N-of-1 trial. So when you read an N-of-1 study, note whether it is a standalone trial meant to guide one patient's treatment or a prospectively planned series aiming at a population claim; they answer different questions.

Reading one with confidence

To appraise an N-of-1 trial, check the same fundamentals you would in any crossover study, scaled to one person. Were the treatment periods randomized in order and, ideally, blinded? Was there a washout suited to how the treatment acts? Were enough pairs run to make a consistent result convincing rather than anecdotal? And is the outcome something meaningful and measurable to that patient, tracked the same way in every period?

If those elements are in place, an N-of-1 trial is a rigorous piece of evidence for the individual it studied, and a reminder that a randomized experiment is defined by its design, not its size. If they are missing, what remains is a structured anecdote, useful perhaps, but not the experiment the label promises.